A subsidiary of OPKO Health, Inc. (NYSE:OPK), a multi-national bio-pharmaceutical and diagnostics company, completed the acquisition of all of the assets and undertaking of Cytochroma Canada Inc., a privately held pharmaceutical company with operations in Markham, Ontario, and Bannockburn, Illinois.

The purchase price paid on closing was approximately US$100 million and was satisfied by the issuance of OPKO common stock to Cytochroma. There is also an earn-out component for up to an additional US$190 million, which is payable upon the satisfaction of certain regulatory and revenue milestones.

Cytochroma Canada Inc. was represented in Canada by Aird & Berlis LLP with a team that included Richard Kimel, Tom Fenton, James Leech and Anne Markle (corporate finance); Barbara Worndl (tax); Aaron Collins (financial services) and Grant Cansfield (intellectual property); and in the United States by Cooley LLP with a team that included Glen Sato (corporate/securities).

OPKO Health, Inc. was represented in the United States by Akerman Senterfitt LLP with a team that included Mary Carroll, Teddy Klinghoffer, Daniel Schwartz and Alex Goone (corporate & commercial); and in Canada by Blake, Cassels & Graydon LLP with a team that included Graham Smith and Guy Amini (corporate & commercial) and Kathleen Penny (tax).


Aaron T. Collins Richard M. Kimel Barbara J. Worndl R. Grant Cansfield James Leech Anne Miatello Kathleen V. Penny Gahiz (Guy) Amini Tom A. Fenton Graham B. Smith